14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ARVN vs RAPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (52.4/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ARVN wins 3–2 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. ARVN 52.9/100 HOLD) and -0.02β · 2% Vol risk profile, whereas ARVN leads top-line expansion (-98.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARVN vs RAPT. Trailing 12-month operating profitability (ARVN -10.1% vs RAPT 0.0%) and valuation multiples (ARVN 17.9x vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ARVN vs RAPT Key Questions & Quantitative Answers
As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (52.4/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ARVN wins 3–2 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. ARVN 52.9/100 HOLD) and -0.02β · 2% Vol risk profile, whereas ARVN leads top-line expansion (-98.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ARVN leads the Growth & Scale pillar: ARVN posts -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ARVN generates $275M in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, ARVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.
ARVN screens cheaper on headline valuation multiples. ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARVN (-1.8% ROE) versus RAPT (-85.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.